Derivatized calcitonins
OwnerVirender M. Labroo, Tomikazu Sasakiinventors
Life of this patent
Estimating the term…
Abstract
Derivatized calcitonin molecules, pharmaceutical compositions comprising derivatized calcitonins, and methods of reducing serum calcium in a patient using the derivatized calcitonins are disclosed. The molecules are characterized by a derivatized amino terminus formed by combining a calcitonin with a cyclic, polycyclic or heterocyclic moiety. Multimeric forms of the molecules are also disclosed.
Claims26
A compound selected from the group consisting of:
- ##STR19## and pharmaceutically acceptable salts thereof, wherein R is substituted or unsubstituted biaryl, optionally containing 1 or 2 ring nitrogen atoms per ring;
- or substituted or unsubstituted bis-heterocycloalkyl containing 1 or 2 heteroatoms per ring selected from the group consisting of N, S and O.
Compound of the formula R-N-CT, wherein CT is a calcitonin selected from the group consisting of human, salmon, eel, rat, porcine, bovine, ovine and chicken calcitonins and biologically active derivatives and variants thereof, or a pharmaceutically acceptable salt thereof;
- N is an amide linkage;
- and wherein R is substituted or unsubstituted biaryl, optionally containing 1 or 2 ring nitrogen atoms per ring;
- or substituted or unsubstituted bis-heterocycloalkyl containing 1 or 2 heteroatoms per ring selected from the group consisting of N, S and O.
A compound of the formula
- X-(R-N-CT).sub.n
- wherein X is a monovalent, divalent or trivalent ion of a transition metal;
- R is a heterocycloalkyl or heteroaryl group;
- CT is a calcitonin selected from the group consisting of human, salmon, eel, rat, porcine, bovine, ovine and chicken calcitonins and biologically active derivatives and variants thereof;
- N is an amide linkage;
- and n=2 or 3;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.